Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
”Happy to share our new publication in ESMO Open, where we report outcomes from a nationwide population-based cohort of more than 51,000 patients with stage I–III breast cancer, including over 7,500 with invasive lobular carcinoma (ILC).
- Patients with ILC were more often diagnosed with larger tumors and more extensive nodal involvement
- ILC was associated with worse long-term survival in unadjusted analyses, largely reflecting differences in disease presentation (higher stage at diagnosis)
- ILC demonstrated a distinct time-dependent prognostic pattern, with lower early but higher late mortality
- The prognostic impact of lobular histology became increasingly apparent with greater nodal burden
- Patients with ILC and extensive nodal involvement (N3) experienced particularly unfavorable long-term outcomes
These findings emphasize the importance of long-term follow-up in ILC and the need for improved staging, risk stratification and treatment strategies to address late recurrences
A huge thank you to the Belgian Cancer Registry and all co-authors and collaborators who helped make this work possible!”
Title: Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study
Authors: G. Nader-Marta, L. Ameye, D. Martins-Branco, R. Salgado, N. Van Damme, J. Verbeeck, P. Aftimos, L. Buisseret, M. Paesmans, C. Molinelli, E. Mayer, M. Lambertini, K. Van Baelen, C. Desmedt, M. Piccart, E. de Azambuja
Read the Full Article.
Other Articles Featuring Guilherme Nader Marta On OncoDaily.
